Market Research Logo

Global CAR-T Cell Therapy Market – Market Size, Forecasts, Trials & Trends

Global CAR-T Cell Therapy Market – Market Size, Forecasts, Trials & Trends

EXECUTIVE SUMMARY

CAR-T cell therapy is a remarkably promising treatment for cancer patients. This emerging treatment is the biggest breakthrough since the introduction of chemotherapy. Already two products (Kymriah and Yescarta) have been approved by the U.S. FDA and European EMA for different cancer indications.

What is CAR-T Cell Therapy?

Chimeric antigen receptors (CARs) are genetically engineered cells that are developed in the laboratory and infused into a patient to help in detecting and fighting cancer. The protein constructs stimulate anti-cancer T-cells, which in turn boost a patient’s immune system. CAR-T cell therapy is defined as a type of immunotherapy that teaches T cells to recognize and destroy cancer.

CAR-T is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.”

How Does CAR-T Cell Therapy Work?

T-cells form the backbone of CAR-T cell therapy. T-cells are the workhorses of our immune system and they play a key role in directing the immune response and killing cells infected by pathogens. In CAR-T cell therapy, blood is drawn from the patient and the T-cells are separated out. In the laboratory, a disarmed virus is used to genetically engineer the T-cells to produce chimeric antigen receptors (CARs) on their surface. These receptors are synthetic and do not exist naturally. Once infused into the patient, these CARs enable the T-cells recognize and get attached to an antigen (specific protein) on the tumor cell leading to the destruction of the tumor.

Two CAR-T products are available in the market. The first one, Kymriah (Tisagenlecleucel) by Novartis, was approved by U.S. FDA in August 2017. It was approved to be used in children and adults with ALL. On May 1, 2018, FDA approved Kymriah for a second indication (diffuse large B-cell lymphoma). The second CAR-T product, Yescarta (Axicabtagene ciloleucel) by Kite Pharmaceuticals, was approved by FDA in October 2017 for patients with lymphoma.

In August 2018, both Kymriah and Yescarta secured approval in Europe, indicating the willingness of European regulators to usher in a new age of regenerative medicine. In September 2018, Health Canada approved Kymriah as the first CAR-T therapy to receive regulatory approval in Canada.

Like all cancer therapies, CAR-T cell therapy can also cause a number of side effects. However, all these side effects can be managed with standard supportive therapies including steroids. The widespread research activities, worldwide clinical trials and treatments in a limited number of U.S. hospitals have created a robust CAR T-cell market with an estimated CAGR of 6.3% per year. This billion dollar market and projected growth would have been not possible without the remarkable efficacy of Kymriah and Yescarta in treating several types of blood cancers.

Market for CAR-T Cell Therapy

CAR-T cell therapy has swept the biotech industry by storm in recent years, creating hope that it could welcome in a new age of cancer treatment. However, the remarkable success stories have come from targeting CD19, which is now considered an antigen that holds the key to a limited range of blood cancers. Presently, this hematological arena is a highly competitive therapy space that is being shared between among leading CAR-T companies.

Scientists, investors and developers invariably agree that the key to longer-term success in this space depends on solving two major problems: identifying antigens other than CD19 that can be targeted with CAR-T therapy with strong efficacy and going beyond liquid cancers into solid tumor indications. CAR-T cell products to deal with solid tumors will undoubtedly offer a larger market potential.

However, it is not an easy task to identify the antigens found on the cells of solid tumors. There are reasons why CD19 is the most common target. It is seen solely on B cells, whose destruction via CAR-T therapy offers a straightforward route for treating B-cell leukemias and lymphomas. At the same time, loss of the body’s B cells is not particularly problematical, because their antibody-producing function can be reinstated by injecting intravenous immunoglobulin (IVIG) to patients.

Currently, the only two non-CD19-directed CAR-T therapies are those that target CD22 in B-cell malignancies and B-cell maturation antigen (BCMA) in multiple myeloma. CD22 is structurally analogous to CD19, while BCMA is an antigen expressed on plasma cells, whose functional loss can also be replaced with IVIG.

The problem with solid tumors is that there is little evidence of CAR-T being able to overcome the numerous difficulties that exist for these to be targeted efficiently. However, both academic and commercial groups are racing against time to identify the antigens on solid tumor cells and develop suitable CAR-T cells, because it represents large market potential.

There are several reasons which make solid tumors difficult to treat using CAR-T cell therapies. Globally, solid tumors outnumber the hematological tumors by 10 to one. In 2015, Novartis and PENN reported that their CART-meso failed to show any effect in patients with mesothelioma, ovarian cancer and pancreatic cancer. Moreover, there was very poor persistence of CAR-T cells in the patients.

The difficulty with solid tumors is that they are usually surrounded by a hostile, immuno-suppressive microenvironment. This environment presents many inhibitory factors that prevent CAR-T cells from reaching them. A typical CAR-T approach will not have success under these conditions. For this reason, Juno and Novartis are engaging in constructing CAR-T cells with novel designs that incorporate additional elements to boost activity within this setting. Currently, these products are in preclinical development.

Driving Forces for the CAR-T Therapy Market

With growing demand for CAR-T therapies, CAR-T companies are proliferating. Growing numbers of these companies are supported by:

  • Increasing investment flowing into CAR-T cell research
  • Landmark approvals of CAR-T cell therapies by the U.S. Food & Drug Administration (FDA) and the European Medicines Agency (EMA)
  • Major acquisitions within the CAR-T industry
  • Large IPOs within the CAR-T industry
As mentioned, 2017 was the first year that the U.S. FDA approved a CAR-T cell therapy, approving Kymriah in August 2017 and Yescarta in October 2017. Novartis produced Kymriah, a CAR-T therapy used to treat acute lymphoblastic leukemia. Kite Pharma produced Yescarta, a CAR-T therapy to treat adult patients with certain types of large B-cell lymphoma who did not respond to or who relapsed after other kinds of treatment. In August 2018, both Kymriah and Yescarta secured approval in Europe from the EMA.

The approval of these first two CAR-T cell therapies has opened the gates for many other types of cell and gene therapies to claim respect, both from regulators, as well as from the scientific and medical community at large. These historic events demonstrate that CAR-T cell therapy is a market that has emerged, no longer one that is evolving in the future.

CAR-T funding is also on the rise. At first the trend was subtle, but the tide swelled as CAR-T therapies like Kymriah and Yescarta reached the marketplace and created a CAR-T funding craze. CAR-T start-ups have been richly funded by investors eager to get into this trending area of regenerative medicine. Following IPOs by CAR-T players Kite Pharma, Bellicum, Juno Therapeutis and Cellectis totaling over $750 million, CAR-T developer Autolus announced a $150 million IPO.

This has bought the total value of recent CAR-T initial public offerings (IPO’s) to nearly $1 billion.

CAR-T Industry Deal-Making


The CAR-T industry has also witnessed aggressive deal-making in recent years. Celgene snagged Juno Therapeutics for a shocking $9 billion in January 2018 and Gilead acquired Kite Pharma for an astounding $11.9 billion in August 2017. After $20 billion of market capitalization from the CAR-T companies in 2018, the CAR-T market has continued to gain momentum.

There have also been more than a dozen CAR-T deals between pharmaceutical companies and academic institutions, with the best known being the partnership between Novartis and the University of Pennsylvania (UPenn). When Kymriah™ because the first CAR-T cell therapy to be approved in the U.S. in August 2017, it resulted from a 5-year collaboration between UPenn and Novartis.

CAR-T financing rounds have also proliferated. In one major example, Celularity raised $250 million in February 2018 to support development of placental-derived products, including T-cells that will be immune advantaged because of their derivation from the placenta. Celularity is looking to burst a major bottleneck in the industry by deriving T-cells from a single (allogeneic) cell line, potentially positioning itself to slash the price point for CAR-T treatments. In other significant example, London-based CAR-T start-up Allogene Therapeutics entered into an asset contribution deal with Pfizer in April 2018, as well as announced a $300 million Series A round.

To characterize this rapidly expanding marketplace, BioInformant has released a 194-page global strategic report that explores growing demand for CAR-T cell therapies.

Claim it to:

1. Get informed about the rapidly evolving CAR-T market
2. Identify opportunities for CAR-T product development
3. Reveal the identities of competitors developing CAR-T products and technologies
4. Access market size data, market segmentation, and 5-year projections through 2024
5. Determine company strategy or purse funding from investors
6. Make smarter decisions, faster


  • REPORT OVERVIEW
    • Statement of the Report
    • Executive Summary
    • INTRODUCTION
  • SIXTY YEARS HISTORY OF CAR-T CELL THERAPY
    • Timeline of CAR-T Cell Therapy Development
      • Table Timeline of CAR-T Cell Therapy Development
  • CAR-T MANUFACTURING PROCESSES
    • Manufacturing Autologous CAR-T Cells
    • T-CellSource
    • T-Cell Activation
      • Beads-Based T-Cell Activation
      • Antibody-Coated Magnetic Beads
      • Antibody-Coated Nanobeads
      • Expamer Technology
      • Activation with Anti-CD3 Antibodies
    • Genetic Modification of T-Cells
    • Expansion of CAR-T Cells
      • Expansion of CAR-T Cells using GE Bioreactors
      • Expansion of CAR-T Cells using G-Rex Bioreactors
      • Expansion of CAR-T Cells using Prodigy
      • Expansion of CAR-T Cells through Recursive AAPC Stimulation
    • Clinical CAR-T Cell Manufacturing Quality Checkpoints
      • Qualification of Manufacturing Facilities
      • Qualification of Ancillary Components
        • Table Examples of Ancillary Components for Clinical CAR-T Manufacturing
      • Qualification of Manufacturing Process
    • In-Process Testing and Release Testing of Cellular Products
      • Table Examples of CAR-T Cells Release Tests
    • Allogeneic CAR-T Cells
  • STRUCTURE OF A CAR-T CELL
    • First Generation CAR-T Cells
    • Second Generation CAR-T Cells
    • Third Generation CAR-T Cells
    • Fourth Generation CAR-T Cells
    • Mechanism of Action
    • New CAR Models and Concepts
      • Truck CAR
      • Universal CAR
      • Self-driving CAR
      • Armored CAR
      • Self-destruct CAR
      • Conditional CAR
      • TanCAR
      • Dual CAR
      • Safety CAR )sCAR)
    • Basic Components of CAR
      • Common Deigns of CAR-T Constructs
        • Table Different Types of CAR-T Constructs, Corresponding Antigens and Indications
  • NUMBER OF CAR-T COMPANIES, THEIR RECENT ACTIVITIES
    • Geographical Distribution of CAR-T Cell Therapeutic Companies
      • Table Global Distribution of CAR-T Cell Therapeutic Companies
    • Immunocellular Therapy Companies by Cell Type
      • Table Number of Immunocellular Therapy Companies by Cell Type, Worldwide
    • Market Leaders in CAR-T Cell Therapy and their Recent Activities
      • AbbVie
      • Allogene Therapeutics
      • Amgen
      • Agios Pharmaceutical
      • Atara Biotherapeutics
      • Autolus Limited
      • Bellicum Pharmaceuticals
      • bluebird bio
      • Calibr
      • Carina Biotech
      • CARsgen Therapeutics
      • Celgene Corporation
      • Cellectis
      • Cell Medica
      • Cell Design Labs
      • Celularity
      • Celyad
      • Fate Therapeutics
      • Fortress Bio
      • Gilead Sciences
      • Janssen Biotech
      • Juno Therapeutics
      • JW Therapeutics
      • Kite Pharma
      • Medisix Therapeutics
      • Mustang Bio
      • Nanjing Legend Biotech
      • Novartis
      • Pfizer
      • Precision Biosciences
      • Posedia Therapeutics
      • Shire
      • Sorrento Therapeutics
      • Ziopharm
  • TUMOR-ASSOCIATED TARGET ANTIGENS
    • Antigens on Solid Tumors
      • Table Tumor-Associated Antigens of CAR-T Cell Targets
      • Epidermal Growth Factor Receptor (EGFR)
      • Epidermal Growth Factor Receptor Variant III (EGFRvIII)
      • Human Epidermal Growth Factor Receptor-2 (HER2)
      • Mesothelin (MSLN)
      • Prostate-Specific Membrane Antigen (PSMA)
      • Disialoganglioside 2 (GD2)
      • Interleukin-13Rá2 (IL13Rá2)
      • Glypican-3 (GPC3)
      • Carbonic Anhydrase IX (CAIX)
      • L1 Cell Adhesion Molecule (L1-CAM)
      • Cancer Antigen 125 (CA125) (MUC16)
      • Prominin-1 (CD133)
      • Fibroblast Protein-á (FAP-á)
      • Cancer/Testis Antigen 1B (CTAG1B)
      • Mucin 1 (MUC1)
      • Folate Receptor-á (FR-á)
    • CAR-T Targets in Hematologic Malignancies
      • Table CAR Target Antigens for Hematologic Malignancies and Potential Off-Tumor Targets
      • CD19
      • CD20
      • CD22
      • ROR1
      • CD30
      • CD138
      • CD123
      • NKG2D-L
      • BCMA
      • CD174
    • CAR-T Cell Trials Targeting CD19
      • Table Percent (%) Share of CAR-T Cell Trials Targeting CD19
      • Positive CR Rates in CD19 Targeted Studies in Hematological Malignancies
        • Table Outcome of CAR-T Cell Therapy Trials in Liquid Malignancies, Targeting CD19
      • Outcome of CAR-T Cell Therapy Trials Targeting Antigens other than CD19
        • Table Outcome of CAR-T Cell Therapy Trials in Liquid Malignancies, Except CD19
      • Targets other than CD19 in Hematological Cancers
        • Table Most Frequent CAR-T Cell Targets in Liquid Malignancies (Except CD19)
      • CD30 vs. BCMA Targets for Multiple Myeloma
        • Table Trend in Number of CAR-T Cell Therapy Clinical Trials: CD30 vs. BCMA
    • CAR-T Cell Therapy for Solid Tumors
      • Table Clinical Outcome of CAR-T Cell Therapy Trials in Solid Malignancies
      • CAR-T Cell Targets in Solid Malignancies
        • Table Most Frequent CAR-T Cell Targets in Solid Malignancies
  • TARGET DISEASES FOR CAR-T CELL THERAPY
    • Table Target Diseases and Target Antigens
    • Acute Lymphoblastic Leukemia (ALL)
    • Chronic lymphocytic leukemia (CLL)
    • Non-Hodgkin lymphoma
    • Acute myeloid leukemia (AML)
    • Neuroblastoma
    • Multiple myeloma (MM)
  • PRICING AND PAYMENT MODELS FOR CAR-T THERAPIES
    • Controversies over CAR-T Pricing
    • Hospital Mark-up Costs for Kymriah and Yescarta
      • Table Treatment Acquisition Costs and Mark-Up Costs
    • Cost Effectiveness of Tisagenlecleucel and Axicabtagene
      • Table Long-Term Cost-Effectiveness of Tisagenlecleucel and Axicabtagene
    • Value-Based Price Benchmarks
      • Table Value-Based Price Benchmarks
    • Unit Prices Needed to Reach Cost-Effectiveness Thresholds
      • Table Unit Prices Needed to Reach Cost-Effectiveness Thresholds
    • Alternate Payment Strategies
      • Table Alternate Payment Strategies
  • MEDICAL FACILITIES OFFERING CAR-T THERAPIES
    • Table U.S. Medical Facilities Offering CAR-T Cell Therapies
    • CAR-T Recommended in Europe
    • CAR-T Cell Therapy in Chinese Hospital
    • Canada Joins the CAR-T Club
  • CAR-T THERAPY PATENT LANDSCAPE
    • Number of CAR-T Cell Patents, 2013-2018
    • CAR-T Patent Types
      • Table Major CAR-T Patent Holders
    • A Brief Snapshot of CAR-T Patent Landscape
      • Patents for Anti-CD19 CAR-T
      • Patents for Anti-BCMA CAR-T
      • Patents for Regulatable CAR-T
      • Patents for CAR-T for Solid Tumors
        • Table Select List of CAR-T Patents
    • Major CAR-T Patent Applicants
      • Table Major CAR-T Patent Applicants
  • DEALS, FUNDINGS, PARTNERSHIPS AND COLLABORATIONS
    • Funding for CAR-T
      • Table CAR-T Financing Rounds
    • CAR-T Deals
      • Table CAR-T Deals and Partnerships
    • Initial Public Offering (IPO)
      • Table CAR-T Initial Public Offerings (IPOs)
    • Key CAR-T Technology Deals
      • Table Key CAR-T Technology Deals
      • Deal between Juno Therapeutics and Eureka for a Fully Human ScFv Binding Domain
      • Acquisition of Stage Cell Therapeutics by Juno Therapeutics
      • Collaboration between Juno Therapeutics and Editas Medicine
      • Kite and Alpine in Research and License Agreement
      • Johnson & Johnson Gets PiggyBac Technology from Transposagen
      • Johnson & Johnson and Posedia in a Technology Deal
      • Partnership between Baxalta and Precision Biosciences
      • Novartis, Intellia and Caribou
      • Overall Trends in Oncology Licensing, Joint Venture and Research Deals
        • Table Licensing, Joint Venture and Research Only Oncology Deals from 2013-2017
  • THE LANDSCAPE OF CAR-T CELL THERAPY CLINICAL TRIALS
    • The Surge in Number of CAR-T Clinical Trials
      • Table Number of CAR-T Cell Therapy Clinical Trials, 2007-2018
    • Percentage (%) of Total CAR-T Clinical Trials by Target
      • Table Percentage (%) of Total CAR-T Clinical Trials by Target
    • Research Focus on CAR-T Trials by Indication
      • Table Research Focus of CAR-T Trials by Indication
    • Clinical Trials using CAR-T Cells by Country as of 2018
      • Table Clinical Trials using CAR-T Cells by Country as of 2018
    • CAR-T Clinical Trials to Watch
      • Table Four CAR-T Clinical Trials to Watch
    • CAR-T Projects with Commercial Licensees
      • Table Clinical Stage CAR-T Projects with Commercial Licensees (Excluding China)
    • Clinical CAR-T Constructs with Sole Involvement from Academicia
      • Table Clinical CAR-T Constructs with Sole Involvement from Academia
    • Anti-CD19 CAR-T Studies
      • Table Anti-CD19 CAR-T Studies (Excluding China)
    • CAR-T Studies in Multiple Myeloma and Acute Myeloid Leukemia
      • Table List of CAR-T Studies in Myeloma and Acute Myelogenous Leukemia (AML)
    • CAR-T Cell Therapy for Solid Tumors
      • Table A List of Clinical Studies of CAR-T Therapies in Solid Tumors (Excluding China)
    • Studies of CAR-T Projects Transfected using mRNA Electroporation
      • Table Studies of CAR-T Projects Transfected using mRNA Electroporation
    • CAR-T Projects Incorporating Suicide Genes
      • Table CAR-T Projects Incorporating Suicide Genes
    • Early Stage CAR-T Assets
      • Table A Selection of Preclinical CAR-T Projects
    • Anti-CD22 CAR-T Projects
      • Table Anti-CD22 CAR-T Projects in the Clinic
    • Cytokine Release Syndrome (CRS) with CART19 Therapy
      • Table Cytokine Release Syndrome (CRS) with CART19 Therapy
    • CAR-T Therapy Pipeline Distribution by Indication
      • Table CAR-T Therapy Pipeline Distribution by Indication
    • CAR-T Therapy Pipeline Distribution by Target Antigen
      • Table CAR-T Therapy Pipeline Distribution by Target Antigen
    • Distribution of CAR-T Clinical Trials in China
      • Table Distribution of CAR-T Trials in China
      • CD19-Directed CAR-T Clinical Trials in China
        • Table Clinical Trials of CD19-Directed CAR-T Cells in China
      • Chinese Trials Targeting Non-CD19 Antigens
        • Table Chinese Trials Targeting Non-CD19 Antigens
      • Chinese Trials on Solid Tumors
        • Table A Partial List of Chinese Trials on Solid Tumors
      • Chinese Trials Using Fourth Generation CAR Constructs
        • Table Chinese Trials Using Fourth Generation CAR Constructs
      • Clinical Stage CAR-T Projects in China
        • Table Clinical Stage CAR-T Projects in China
  • CAR-T CELL PRODUCTS IN THE MARKET
    • Tisagenlecleucel (Kymriah)
      • Table Development Timeline for Tisagenlecleucel (Kymriah)
      • Evidences Supporting Effectiveness of Tisagenlecleucel (Kymriah)
      • Medical Necessities for Tisagenlecleucel (Kymriah)
      • Overall Remission Rates in Patients Treated with Kymriah
        • Table Overall Remission Rates in Therapies for r/r Childhood B-ALL
      • Overall Event-Free Survival Rate with Tisagenlecleucel (Kymriah)
        • Table Estimated Event-Free Survival at Six and 12 Months in Therapies for r/r Childhood B-ALL
      • Key Adverse Events in ELIANA Trial
        • Table Key Adverse Events in ELIANA Trial (N=68)
      • Key Adverse Events in JULIET Trial
        • Table Key Adverse Events in the JULIET Trial (N = 99)
      • Budget Impact for Tisagenlecleucel
        • Table Per-Patient Budget Impact Calculations for Tisagenlecleucel Over a Five-Year Time Horizon, Assuming 400 Patients per year over Five Years
      • Overall Adverse Events with Tisagenlecleucel
        • Table Grade 3 or Higher Adverse Events Experienced by Patients in the First Eight Weeks Following Tisagenlecleucel Infusion
      • Per-Patient Potential Budget Impact of Tisagenlecleucel
        • Table Estimated Annualized Total Potential Budget Impact (BI) of Tisagenlecleucel Using Different Prices over a Five-Year Time Horizon, Assuming 617 Eligible Patients per Year
    • Axicabtagene Ciloleucel (Yescarta)
      • Evidences to Support the Effectiveness of Axicabtagene Ciloleucel
        • Table Development Timeline for Axicabtagene Ciloleucel (Yescarta)
      • Medical Necessities for Axicabtagene Ciloleucel (Yescarta)
      • Clinical Benefits of Axicabtagene Ciloleucel (Yescarta)
      • Objective Response Rates (ORR) for Axicabtagene Ciloleucel
        • Table Objective Response Rates (ORR) Reported for Axicabtagene Ciloleucel
      • CRR for Axicabtagene Ciloleucel
        • Table CRR for Axicabtagene Ciloleucel for r/r Adult B-Cell Lymphoma Compared with SCHOLAR-1
      • Adverse Events in ZUMA-Trial
        • Table Key Adverse Events in the ZUMA-1 Trial (N=101)
      • Base-Case Results
        • Table Base-Case Discounted Lifetime Costs and Outcomes
      • Value-Based Benchmark Prices
        • Table Value-Based Price Benchmarks for Tisagenlecleucel and Axicabtagene Ciloleucel
      • Per-Patient Budget Impact of Axicabtagene Ciloleucel
        • Table Per-Patient Budget Impact Calculations for Axicabtagene Ciloleucel over a Five-Year Time Horizon, Assuming 5,902 Patients per Year over Five Years
      • Unit Cost for Healthcare Utilization in CAR-T Therapy
        • Table Unit Cost for Healthcare Utilization in CAR-T Therapy
        • Table Adverse Events Unit Cost
  • INSURANCE COVERAGE FOR CAR-T THERAPY
    • Coverage Policies for Tisagenlecleucel – B-ALL Patients
    • Coverage for Stem Cell Transplantation (SCT) –B-Cell ALL Patients
    • Coverage for Axicabtagene Ciloleucel – B-Cell NHL Patients
    • Coverage for Stem Cell Plantation (SCT) in B-Cell NHL Patients
    • Insurance Coverage by Medicare and Medicaid
  • COMMERCIAL THREATS FOR CAR-T INDUSTRY
    • Competition in a Narrow Field
    • Competition from other Technologies
    • Threat from TCRs
    • Threat of Litigation
  • CHALLENGES TO OVERCOME
    • Lack of Persistence
    • Inadequate Activation
    • Transfection Method
    • Humanized Binding Domains
    • Antigen Escape
    • Lineage Switching
    • Lack of Safety
    • Benefits of CAR-T Cell Therapy
    • CAR-T Cell Therapy: Only the Beginning of the Story
    • A New Standard
  • MARKET ANALYSIS
    • Table Global Market for CAR-T Cell Therapies, 2018-2023
    • Global Market for CAR-T Therapy by Geography
    • Global Market for CAR-T Therapy by Country
    • Global Market for CAR-T Cell Therapy by Targeted Antigens
    • Competitive Landscape
      • Table CAR-T Therapy – Competitive Landscape
  • COMPANY PROFILES
    • AbbVie Inc.
      • Collaboration with Calibr
    • Adaptimmune Therapeutics PLC
      • Pipeline
        • Table Adaptimmune's Product Pipeline
    • Amgen, Inc.
      • Amgen's Collaboration with Kite Pharma
      • Amgen's Collaboration with MD Anderson Cancer Center
    • Atara Biotherapeutics, Inc.
      • Technology
        • Table Atara's Robust T-Cell Immunotherapy Pipeline
      • Atara tab-cel™
      • Atara ATA188
      • Atara ATA230
    • Aurora Biopharma, Inc.
      • CAR-T for Glioblastoma
    • Autolus Therapeutics PLC
      • Technology
    • Bellicum Pharmaceuticals, Inc.
      • GoCAR Technology
        • Table Bellicum's Product Pipeline
      • BPX-501
      • BPX-601
      • BPX-701
    • BioAtla LLC
      • Conditionally Active Biologics (CABs)
      • Agreement with Pfizer
      • Agreement with Sinobioway
    • bluebird bio
      • Technology
        • Table bluebird bio's Cancer Immunotherapy Pipeline
    • Carina Biotech
      • Technology
    • CARsgen Therapeutics, Ltd.
      • Table CARsgen Therapeutics' Pipeline
    • CARTherics
    • Cellectis
      • Products
    • Celularity
      • Table Celularity's Immuno-Oncology Pipeline
    • Celyad SA
      • Table Celyad's Pipeline
    • Creative Biolabs
    • DiaCarta, Inc.
      • Personalized CAR-T Immunotherapy Platform
    • Endocyte, Inc.
      • LU-PSMA-617
      • Adaptor-Controlled CAR-T Therapy
    • F1 Oncology, Inc.
      • Conditionally Active Biologics (CAB) Technology
    • Fate Therapeutics Inc.
      • Table Fate Therapeutics' Immuno-Oncology Product Pipeline
    • Humanigen, Inc.
      • Ifabotuzumab
    • Immune Therapeutics, Inc.
      • CAR-T from Immune Therapeutics
        • Table Intrexon's CAR-T Pipeline
    • Intrexon, Corp.
      • Table Intrexon's CAR-T Pipeline
    • Juno Therapeutics, Inc.
      • Table Juno's CAR-T Programs
    • Kite Pharma, Inc.
      • Product
        • Table Kite Parma's Product Candidates
    • Lion TCR Pte Ltd.
      • Technology
        • Table Lion's Pipeline
    • MaxCyte, Inc.
      • CARMA Platform
    • Mesoblast, Ltd.
      • Partnership with Cartherics
    • Minerva Biotechnologies Corp.
      • Solid Tumor Cancer Portfolio
      • Antibody Therapeutic for MUC1* Positive Cancers
      • Anti-Metastasis Antibody
      • MUC1*
    • Mustang Bio, Inc.
      • Table Mustang Bio's Pipeline of Product Candidates
    • Novartis AG
      • Kymriah (Tisagenlecleucel)
    • Oxford BioMedica PLC.
      • LentiVector Platform
        • Table Oxford BioMedica's Product Pipeline
    • PeproMene Bio Inc.
      • BAFFR R CAR-Cell
        • Table PeproMene's Pipeline
    • Pfizer, Inc.
      • Asset Contribution Agreement with Allogene Therapeutics
    • Posedia Therapeutics Inc.
      • Table Posedia's Pipeline
    • Precision Biosciences, Inc.
      • Precision Biosciences' Cancer Immunotherapy
    • ProMab Biotechnologies Inc.
      • Table CAR-T Products from ProMab
    • Servier Oncology
      • Table Servier's Oncology Pipeline
    • Sorrento Therapeutics, Inc.
      • Table Sorrento's Immuno-Oncology Products
    • TC Biopharm Ltd.
      • ImmuniCAR
      • OmniCAR
      • OmnImmune
    • Tessa Therapeutics Pte Ltd.
      • TT10 EBVSTs
      • TT12 Armored HPVSTs
      • TT14 GPC3-CAR VSTs
      • TT16 HER2-CAR VSTs
    • TILT Biotherapeutics Ltd.
      • Technology
    • Tmunity Therapeutics Inc.
      • Technology
    • TrakCel Ltd.
    • Xyphos
      • ConvertibleCAR Technology
    • ZIOPHARM Oncology, Inc.
      • IL-12 Platform
      • Sleeping Beauty
        • Table Ziopharm's Product Candidates

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report